

Studienverzeichnis Tumor Zentrum Aarau

Frühere klinische Studien, die am Tumor Zentrum Aarau
durchgeführt worden sind

Stand: 30. Juli 2020

Brustkrebs (1/3)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
SAKK 24/06	II	Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial.	2008	1
IBCSG 24/02 - SOFT	III	A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer	2011	2
SAKK 24/09	III	Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial	2012	3
TANIA - MO22998	III	A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment	2015	3

Brustkrebs (2/3)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
IBCSG 22/00	III	Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer	2016	9
SAKK 22/10	II	A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer	2016	1
3144A2 3005	II	A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer	2018	1
IBCSG 35/07 SOLE	III	A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer	2018	8
MonaLEESA7	III	A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer	2019	2

Brustkrebs (3/3)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
3144A2-3004-WW / B1891004	III	A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer	2019	5
MonaLEESa3	III	MONALEESA-3: A randomized double-blind, placebocontrolled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment	2020	3

Urologische Tumoren

Studie	Phase	Beschreibung	Studien-Ende	Patienten
Seqond	Registry	QoL in 2nd line therapy	2015	10
TAK-700 - C21004	III	A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer	2016	4
212082PCR4001	Registry	A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer	2018	15
Stampede	II/III	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy A multi-arm multi-stage randomised controlled trial	Follow-up	3

Gastrointestinale Tumoren (1/2)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
SAKK 41/03	I/II	Oxaliplatin, irinotecan and capecitabine as a combination regimen for first line reatment of advanced or metastatic colorectal cancer. A multicenter phase I-II trial	2007	1
SAKK 76/02	II	Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery	2010	1
SAKK 41/07	II	Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial	2010	1
SAKK 41/06	III	Bevacizumab maintenance versus no maintenance after stop of first-line chemotherapy in patients with metastatic colorectal cancer. A randomized multicenter phase III non-inferiority trial.	2012	9
ML18147	III	A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease progression under first-line standard CTx / Bevacizumab combination.	2013	2

Gastrointestinale Tumoren (2/2)

Studie	Phase	Beschreibung	Studien-Ende	Patienten
MAVERICC ML25710	II	A randomized Phase II study of Bevacizumab/mFOLFOX6 vs Bevacizumab/mFOLFOFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer	2015	2
QuoliTrap	IV	Beobachtungsstudie zur Erfassung der Lebensqualität bei Patienten mit metastasiertem kolorektalem Karzinom unter Zaltrap® Therapie (QoLiTrap)	Follow up	1
I4T-MC-JVDD	IV	Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry	Follow up	7

Lunge

Studie	Phase	Beschreibung	Studien-Ende	Patienten
NEXT - EMR 062 240-506	IIIb	Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m ² weekly and 500 mg/m ² every two weeks maintenance therapy after platinum-based chemotherapy in combination with cetuximab as first-line treatment for subjects with advanced non-small cell lung cancer (NSCLC)	2013	2
M11-089	III	Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)	2018	2

Diverse Indikationen

Studie	Phase	Beschreibung	Studien-Ende	Patienten
START		Swiss Taxotere Alopecia Prevention Trial	2011	9
BEVLIN - MO21609	II	An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma	2012	1
SOMPAS - 20070626		A prospective non-interventional evaluation of the management of symptomatic anemia in patients receiving myelotoxic chemotherapy for colorectal cancer, breast cancer and lung cancer in Switzerland	2013	4
Proskin		Prospective, observational practice survey of applied skin care and management of Cetuximab related skin reactions	2015	5
MENAC		A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing chemotherapy.	2019	3
SAKK 35/14	II	Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial.	Follow up	1